13D Filing: Tang Capital Partners LP and Cyclacel Pharmaceuticals Inc. (CYCC)

Page 6 of 7 – SEC Filing

Shared power to vote or direct the vote:
Tang Capital Partners, LP
336,747 shares
Tang Capital Management, LLC
336,747 shares
Kevin C. Tang
336,747 shares
Sole power to dispose or direct the disposition:
Tang Capital Partners, LP
0 shares
Tang Capital Management, LLC
0 shares
Kevin C. Tang
0 shares
Shared power to dispose or direct the disposition:
Tang Capital Partners, LP
336,747 shares
Tang Capital Management, LLC
336,747 shares
Kevin C. Tang
336,747 shares
(c)
On November 16, 2017, Tang Capital Partners, LP sold 21,342 shares of Common Stock through the open market at a weighted-average price of $1.78 per share.
On November 17, 2017, Tang Capital Partners, LP sold 35,033 shares of Common Stock through the open market at a weighted-average price of $1.75 per share.
On November 20, 2017, Tang Capital Partners, LP sold 44,198 shares of Common Stock through the open market at a weighted-average price of $1.74 per share.
On November 21, 2017, Tang Capital Partners, LP sold 99,427 shares of Common Stock through the open market at a weighted-average price of $1.81 per share.
On November 22, 2017, Tang Capital Partners, LP sold 23,153 shares of Common Stock through the open market at a weighted-average price of $1.82 per share.
(d)          N/A.
(e)
On August 8, 2017, the Reporting Persons ceased to be the beneficial owner of more than five percent of the Issuer’s Common Stock.

Follow Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)